TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23083653

Group type: EXPERIMENTAL
Intervention: Retropubic mid urethral sling
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Transobturator mid urethral sling
Number of subjects: 597
Study: 20520370

Group type: EXPERIMENTAL
Intervention: Hygiene-based nonpharmaceutical interventions (NPIs) including hand washing, sanitizer use, and covering coughs and sneezes.
Number of subjects: 0
Study: 18762955

Group type: EXPERIMENTAL
Intervention: Omentoplasty
Number of subjects: 943

Group type: COMPARATOR
Intervention: No omentoplasty
Number of subjects: 943
Study: 15875527

Group type: EXPERIMENTAL
Intervention: Cetirizine hydrochloride, 10 mg/d
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Fexofenadine hydrochloride, 120 mg/d
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Loratadine, 10 mg/d
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo (lactose), twice daily
Number of subjects: 113
Study: 12821423

Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 251

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 251
Study: 10451399

Group type: EXPERIMENTAL
Intervention: Formula containing 0.9 mg/litre iron
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Formula containing 1.2 mg/litre iron
Number of subjects: 493

Group type: COMPARATOR
Intervention: Cows' milk as before
Number of subjects: 493
Study: 9772613

Group type: EXPERIMENTAL
Intervention: Shuizhi Tuyuan Powder (SZTYP) combined with nifedipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nifedipine (control group)
Number of subjects: 0
Study: 1877559

Group type: EXPERIMENTAL
Intervention: Surfactant (Survanta)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (air)
Number of subjects: 36
Study: 7122662

Group type: EXPERIMENTAL
Intervention: Diazepam (0.3 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 30518646

Group type: EXPERIMENTAL
Intervention: gB/MF59 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28977167

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Apple juice (CON)
Number of subjects: 18
Study: 26607778

Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin (PC)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Cisplatin, cyclophosphamide and epirubicin (CEP)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Adjuvant concurrent chemoradiotherapy followed by chemotherapy
Number of subjects: 112
Study: 25316464

Group type: EXPERIMENTAL
Intervention: Systemic doxycycline
Number of subjects: 76

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 76
Study: 22965590

Group type: EXPERIMENTAL
Intervention: 0.3‐mg ranibizumab
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: 0.5‐mg ranibizumab
Number of subjects: 759

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.3‐mg and 0.5‐mg)
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Composite outcome (photographic changes + clinically important events)
Number of subjects: 759
Study: 20027352

Group type: EXPERIMENTAL
Intervention: Anaferon in complex therapy
Number of subjects: 0
Study: 17968162

Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic colectomy (HALC)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Open colectomy (OC)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both HALC and OC
Number of subjects: 81
Study: 15494201

Group type: EXPERIMENTAL
Intervention: Sedative music (30 min)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Scheduled rest
Number of subjects: 61

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 61
Study: 11479782

Group type: EXPERIMENTAL
Intervention: Homeopathic treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9749809

Group type: EXPERIMENTAL
Intervention: Educational game (G)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Conventional method (CM)
Number of subjects: 131
Study: 7849442

Group type: EXPERIMENTAL
Intervention: Octreotide (100 micrograms bolus followed by continuous intravenous infusion at 25 micrograms/h for 24 hours; 100 micrograms t.i.d. subcutaneously for 6 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Terlypressin (2 mg intravenous bolus every 4 hours for 24 hours; 2 mg every 6 hours on the 2nd day; 1 mg every 6 hours from the 3rd to 7th days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Terlypressin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study: 3059450

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (3 g)
Number of subjects: 29

Group type: COMPARATOR
Intervention: prednisolone phosphate sodium (30 mg)
Number of subjects: 29
Study: 30726338

Group type: EXPERIMENTAL
Intervention: Teaching program for hospital discharge (oral guidance, written instruction, telephone follow-up)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Teaching program for hospital discharge
Number of subjects: 68

Group type: COMPARATOR
Intervention: Routine guidance from the service
Number of subjects: 68
Study: 28806992

Group type: EXPERIMENTAL
Intervention: 12-month clustered campaign program (12 group-based visits delivered in three, 4-week clusters)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Self-directed program (provision of printed intervention materials but no additional treatment visits)
Number of subjects: 108
Study: 25415805

Group type: EXPERIMENTAL
Intervention: Patiromer (4.2 g or 8.4 g twice a day for 4 weeks)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 22433185

Group type: EXPERIMENTAL
Intervention: 40 mg L-759274
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: 1-6 mg lorazepam
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study: 22035427

Group type: EXPERIMENTAL
Intervention: Midwife-led care (MLU)
Number of subjects: 1653
Study: 18327829

Group type: EXPERIMENTAL
Intervention: Psychological and neurological testimony (presence of MRI indicating a brain lesion and testimony about brain injury)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Psychological and neurological testimony (influence on decision-making)
Number of subjects: 396
Study: 16882822

Group type: EXPERIMENTAL
Intervention: Brief psychosocial support from a member of the primary care team, with or without medication
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Primary care-delivered psychosocial interventions
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Indirect psychosocial/behavioral interventions (e.g., anticipatory guidance, treatment adherence)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Provider training to enhance psychosocial skills
Number of subjects: 37
Study: 12821755

Group type: EXPERIMENTAL
Intervention: Statin treatment (anticholesterol drugs)
Number of subjects: 37
Study: 10849926

Group type: EXPERIMENTAL
Intervention: Oral solution in Myvacet 9-08
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Suspension of phenobarbital
Number of subjects: 7

Group type: COMPARATOR
Intervention: Tablet of phenobarbital
Number of subjects: 7
Study: 8992495

Group type: EXPERIMENTAL
Intervention: Norepinephrine (NE) administration
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Indomethacin pretreatment with NE
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dextrose 5%
Number of subjects: 8
Study: 1379106

Group type: EXPERIMENTAL
Intervention: alfuzosin 1.25 mg
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: alfuzosin 2.5 mg
Number of subjects: 93

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 93
Study: 6707391

Group type: EXPERIMENTAL
Intervention: PRW therapy (4 injections)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo therapy (4 injections)
Number of subjects: 63

Group type: COMPARATOR
Intervention: No injections (control group)
Number of subjects: 63
Study: 29477903

Group type: EXPERIMENTAL
Intervention: Web-based personalized feedback intervention for alcohol risk reduction
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Web-based personalized feedback intervention for sexual assault risk reduction
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Web-based personalized feedback intervention for combined alcohol and sexual assault risk reduction
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control condition (full or minimal assessment)
Number of subjects: 264
Study: 26729211

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low dose (L)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Medium dose (M)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High dose (H)
Number of subjects: 40
Study: 25908774

Group type: EXPERIMENTAL
Intervention: Remote rhythm monitoring with anticoagulation based on AT detection
Number of subjects: 2718

Group type: COMPARATOR
Intervention: Usual office-based follow-up with anticoagulation determined by standard clinical criteria
Number of subjects: 2718
Study: 23616630

Group type: EXPERIMENTAL
Intervention: Ethanol ablation (EA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ethanol ablation (EA) and Radiofrequency ablation (RF)
Number of subjects: 50
Study: 20674390

Group type: EXPERIMENTAL
Intervention: Progressive exercise program with weekly supervision
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual activity (control)
Number of subjects: 100
Study: 18426821

Group type: EXPERIMENTAL
Intervention: Metformin (1 g twice daily)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Repaglinide (2 mg thrice daily)
Number of subjects: 96
Study: 16635750

Group type: EXPERIMENTAL
Intervention: FTY720 (0.5, 2.5, or 5mg FTY/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: FTY720 (0.25mg FTY/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: FTY720
Number of subjects: 14
Study: 14668594

Group type: EXPERIMENTAL
Intervention: Parks retractor
Number of subjects: 30

Group type: COMPARATOR
Intervention: Scott retractor
Number of subjects: 30
Study: 10616075

Group type: EXPERIMENTAL
Intervention: N-methyl-D-aspartate antagonist Selfotel
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Intracranial hypertension (ICP > or = 20 mm Hg)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Cerebral perfusion pressure (CPP > 60 mm Hg)
Number of subjects: 427
Study: 9169302

Group type: EXPERIMENTAL
Intervention: Inositol 12 g daily for 4 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Inositol 18 g for 6 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Inositol 12 g daily for 1 month
Number of subjects: 28

Group type: COMPARATOR
Intervention: Inositol 6 g daily for 1 month
Number of subjects: 28

Group type: COMPARATOR
Intervention: Inositol 200 mg/kg body weight for 8 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Inositol 200 mg/kg daily for a crossover trial
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Inositol 6 g daily for 5 days before ECT
Number of subjects: 28
Study: 8289407

Group type: EXPERIMENTAL
Intervention: GLN-containing total parenteral nutrition (TPN) (40 g of glutamine total)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard total parenteral nutrition (TPN) (control)
Number of subjects: 23
Study: 3026015

Group type: EXPERIMENTAL
Intervention: Sulbactam (50 mg/kg per day) and ampicillin (400 mg/kg per day)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Chloramphenicol and ampicillin
Number of subjects: 81
Study: 30275753

Group type: EXPERIMENTAL
Intervention: Radial shockwave therapy (0.17mJ/mm2, 100 impulses/cm2, 5 Hz)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focused shockwave therapy (0.173mJ/mm2, 100 impulses/cm2, 5 Hz)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard wound care (SWC)
Number of subjects: 0
Study: 26908801

Group type: EXPERIMENTAL
Intervention: IIV-HD (High-Dose Inactivated Influenza Vaccine)
Number of subjects: 7643

Group type: COMPARATOR
Intervention: IIV-SD (Standard-Dose Inactivated Influenza Vaccine)
Number of subjects: 7643
Study: 24881861

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 1612

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 1612
Study: 24131759

Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone acetonide (single injection)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone acetonide (repeat injection at 21-day interval)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no corticosteroid injection)
Number of subjects: 60
Study: 21927044

Group type: EXPERIMENTAL
Intervention: Automatic adjustment of spinal cord stimulation amplitude
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual adjustment of spinal cord stimulation amplitude
Number of subjects: 20
Study: 18185520

Group type: EXPERIMENTAL
Intervention: Cotransplantation of mesenchymal stem cells (MSCs), median number infused: 3.4 x 10(5) kg(‐1) (range, 0.3‐15.3 x 10(5) kg(‐1))
Number of subjects: 25

Group type: COMPARATOR
Intervention: HLA‐identical sibling‐matched hematopoietic stem cells (HSC) without MSCs (non-MSCs group)
Number of subjects: 25
Study: 16343417

Group type: EXPERIMENTAL
Intervention: Mastic chewing gum
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 25
Study: 14607583

Group type: EXPERIMENTAL
Intervention: Complete hatching using the Zona Infrared Laser Optical System (ZILOS)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Partial hatching using the Zona Infrared Laser Optical System (ZILOS)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (no laser treatment)
Number of subjects: 114
Study: 10974832

Group type: EXPERIMENTAL
Intervention: Accelerated fractionation radiotherapy (7 fx a week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional radiotherapy (5 fx a week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined treatment (total laryngectomy + postoperative RT)
Number of subjects: 0
Study: 8816612

Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 mg/wk)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 1579279

Group type: EXPERIMENTAL
Intervention: Experimental group (E) - parents brought only their sick child into the examining room
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (C) - parents brought their well children along with their sick child into the examining room
Number of subjects: 49
Study: 3915460

Group type: EXPERIMENTAL
Intervention: Penbutolol 20 mg + Piretanide 3 mg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Penbutolol 40 mg + Piretanide 6 mg
Number of subjects: 108

Group type: COMPARATOR
Intervention: Penbutolol 20 mg
Number of subjects: 108
Study: 29797226

Group type: EXPERIMENTAL
Intervention: Contra-lesional cerebellar tDCS
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ipsi-lesional cerebellar tDCS
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ipsi-lateral cerebellar stimulation in healthy controls
Number of subjects: 15
Study: 27442637

Group type: EXPERIMENTAL
Intervention: Repeat transforaminal epidural steroid injection (TFESI) at 2 to 3 weeks after the first injection
Number of subjects: 184

Group type: COMPARATOR
Intervention: Intermittent transforaminal epidural steroid injection (TFESI) only for pain aggravation
Number of subjects: 184
Study: 24670570

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 23141790

Group type: EXPERIMENTAL
Intervention: Mild shock or surprise stimuli exposure for one twin during a 12-minute period; physiological responses recorded in the second twin.
Number of subjects: 8
Study: 21029903

Group type: EXPERIMENTAL
Intervention: Mechanical microkeratome (Carriazo‐Barraquer)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Femtosecond laser (IntraLase)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (Mechanical microkeratome and Femtosecond laser)
Number of subjects: 50
Study: 18545825

Group type: EXPERIMENTAL
Intervention: Group A - Lateral decubitus position facing away from the ventilator (Pcuff A1)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Group A - Return to initial position (Pcuff A2)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Group A - Lateral decubitus position facing the ventilator (Pcuff A3)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Group A - Return to initial position (Pcuff A4)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Group B - Lateral decubitus position facing the ventilator (Pcuff B1)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Group B - Return to initial position (Pcuff B2)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Group B - Lateral decubitus position facing away from the ventilator (Pcuff B3)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Group B - Return to initial position (Pcuff B4)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Overall measurements
Number of subjects: 70
Study: 19855315

Group type: EXPERIMENTAL
Intervention: Carbamazepine (100 mg three times daily for 7 days)
Number of subjects: 12
Study: 15066920

Group type: EXPERIMENTAL
Intervention: Four-group risk communication intervention varying information on CRC risk factors and tailored feedback.
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: Four-group risk communication intervention
Number of subjects: 860
Study: 11570312

Group type: EXPERIMENTAL
Intervention: Monthly injectable combination hormone contraceptive
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral contraceptive
Number of subjects: 0
Study: 9720517

Group type: EXPERIMENTAL
Intervention: UroPhos-K (4 tablets twice daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 8147942

Group type: EXPERIMENTAL
Intervention: Promazine (100 mg orally)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (150 mg orally)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Promethazine (75 mg orally)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Promazine (20 mg intravenously)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (50 mg intravenously)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Promethazine (50 mg intravenously)
Number of subjects: 12
Study: 2849461

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with cisplatin (70 mg/m2) and etoposide (100 mg/m2), given every third week for a maximum of 4 cycles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy (42 Gy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with cisplatin and etoposide
Number of subjects: 0
Study: 31121903

Group type: EXPERIMENTAL
Intervention: Smog warning system
Number of subjects: 1328

Group type: COMPARATOR
Intervention: Control group (no smog warning)
Number of subjects: 1328
Study: 29474863

Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise training for 24 weeks
Number of subjects: 61
Study: 26455512

Group type: EXPERIMENTAL
Intervention: Enalapril + Folic Acid (10 mg enalapril and 0.8 mg folic acid)
Number of subjects: 20702

Group type: COMPARATOR
Intervention: Enalapril alone (10 mg enalapril)
Number of subjects: 20702

Group type: EXPERIMENTAL
Intervention: Enalapril + Folic Acid
Number of subjects: 20702
Study: 23846159

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) 70 mL
Number of subjects: 9

Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (PLA)
Number of subjects: 9
Study: 22127418

Group type: EXPERIMENTAL
Intervention: Remote monitoring follow-up (active group)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 538
Study: 19715804

Group type: EXPERIMENTAL
Intervention: Intraperitoneal analgesic (levobupivacaine 0.5%)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (0.9% NaCl)
Number of subjects: 71
Study: 17344574

Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic gallbladder drainage (PTGD)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 101
Study: 15613148

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 0
Study: 12189242

Group type: EXPERIMENTAL
Intervention: Intradialytic parenteral nutrition (IDPN)
Number of subjects: 7
Study: 11021270

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) and insulin-like growth factor-I (IGF-I) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 7567587

Group type: EXPERIMENTAL
Intervention: 50% tilt biphasic waveform
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 65% tilt biphasic pulse
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 80% tilt biphasic shocks
Number of subjects: 30
Study: 2190054

Group type: EXPERIMENTAL
Intervention: Topically applied 2% diphemanil methylsulfate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Topically applied placebo
Number of subjects: 15
Study: 340980

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Total series
Number of subjects: 239
Study: 30844507

Group type: EXPERIMENTAL
Intervention: Intraoperative lidocaine infusion (1.5mg/kg bolus followed by 2 mg/kg/h)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Perioperative pregabalin (300mg preoperatively, 75mg twice daily for 9 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo for lidocaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo for pregabalin
Number of subjects: 100
Study: 28043872

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein formula (EHCF) + Lactobacillus rhamnosus GG (LGG)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Extensively hydrolyzed casein formula (EHCF)
Number of subjects: 220
Study: 25922848

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) therapy
Number of subjects: 0
Study: 23590727

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duloxetine 60/120 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0